Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPA
NCT05008926Phase 3Suspended
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Mar 2022
- Primary completion
- Oct 2027
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of naloxegol in opioid-induced constipation (OIC), ventilator-associated pneumonia (VAP), sponsored by Centre Hospitalier Universitaire de Brest. Started Mar 2022; status: suspended.
02
Drugs
naloxegol
03
Conditions
opioid-induced constipation (OIC)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT05008926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05008926.